Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 4/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12388999 | 0.94 | CSNK2A2 (0.32) | CSNK2A2CSNK2A1 | |
| SCHEMBL9912351 | 0.89 | — | — | |
| SCHEMBL14943003 | 0.88 | CSNK2A2 (0.31) | CSNK2A2CSNK2A1 | |
| SCHEMBL10100148 | 0.88 | — | — | |
| SCHEMBL13532213 | 0.86 | PIK3CD (0.34) | PIK3CD | |
| SCHEMBL11924463 | 0.82 | DOT1L (0.30) | — | |
| SCHEMBL9912348 | 0.82 | DOT1L (0.30) | — | |
| SCHEMBL12306914 | 0.82 | — | — | |
| SCHEMBL13532223 | 0.81 | — | — | |
| SCHEMBL14314774 | 0.81 | CSNK2A2 (0.35) | CSNK2A2CSNK2A1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440813-B2 | Antiviral nucleoside analogs | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2114980-B1 | ANTIVIRAL NUCLEOSIDE ANALOGS | BIOCRYST PHARM INC (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20100015094-A1 | ANTIVIRAL NUCLEOSIDE ANALOGS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100015094-A1 | ANTIVIRAL NUCLEOSIDE ANALOGS | TYMP, SAMHD1, TYMS | CSNK2A2 3359/4885CSNK2A1 2946/4885PIK3CD 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.